Autocrine over expression of fibronectin by human transitional carcinoma cells impairs bacillus Calmette-Guerin adherence and signaling

Journal of Urology

Volumn 172, Issue 4 I, 2004, Pages 1496-1500

  Zhang, Guangjian ^a   Chen, Fanghong ^a   Xu, Yong ^b   Cao, Yanli ^a   Crist, Scott ^c   McKerrow, Amy ^c   Iwamoto, Yoshiki ^a   See, William A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Bladder; Carcinoma, transitional cell; Fibronectin; Integrin alpha5beta1; Mycobacterium bovis

Indexed keywords

ANTIBODY; AUTOCRINE MOTILITY FACTOR; BCG VACCINE; FIBRONECTIN; FIBRONECTIN RECEPTOR; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL LINE; CELL SURFACE; CONTROLLED STUDY; CROSS LINKING; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MYCOBACTERIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR CELL;

EID: 4544309705     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000140193.95528.91     Document Type: Article

References (20)

1. Malkowicz, S. B.: Intravesical therapy for superficial bladder cancer. Semin Urol Oncol, 18: 280, 2000
2. Böhle, A., Jocham, D. and Bock, P. R.: Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol, 169: 90, 2003
3. Sylvester, R. J., van der Meijden, A. P. and Lamm, D. L.: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol, 168: 1964, 2002
4. Kim, J. C. and Steinberg, G. D.: The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. J Urol, 165: 745, 2001
5. Cookson, M. S., Herr, H. W., Zhang, Z.-F., Soloway, S., Sogani, P. C. and Fair, W. R.: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol, 158: 62, 1997
6. Davis, J. W., Sheth, S. I., Doviak, M. J. and Schellhammer, P. F.: Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol, 167: 494, 2002
7. Cheng, D. L.-W., Shu, W.-P., Choi, J. C. S., Margolis, E. J., Droller, M. J. and Liu, B. C.-S.: Bacillus Calmette-Guérin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity. J Urol, 152: 1275, 1994
8. Zhao, W., Schorey, J. S., Bong-Mastek, M., Ritchey, J., Brown, E. J. and Ratliff, T. L.: Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced anti-tumor activity. Int J Cancer, 86: 83, 2000
9. Hudson, M. A., Catalona, W. J., Ritchey, J. K., Aslanzadeh, J., Brown, E. J. and Ratliff, T. L.: Choice of an optimal diluent for intravesical bacillus Calmette-Guerin administration. J Urol, 142: 1438, 1989
10. Witjes, J. A., vd Meijden, A. P., Doesburg, W. and Debruyne, F. M.: Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guerin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group. Eur Urol, 23: 366, 1993
11. Kavoussi, L. R., Brown, E. J., Ritchey, J. K. and Ratliff, T. L.: Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an anti-tumor response. J Clin Invest, 85: 62, 1990
12. Chen, F., Zhang, G., Iwamoto, Y. and See, W. A.: Bacillus Calmette-Guerin initiates intracellular signaling in a transitional carcinoma cell line by cross-linking α5β1 integrin. J Urol, 170: 605, 2003
13. Elliott, A. Y., Bronson, D. L., Stein, N. and Fraley, E. E.: In vitro cultivation of epithelial cells derived from tumors of the human urinary tract. Cancer Res, 36: 365, 1976
14. Zhang, G.-J., Ladehoff, D., Xu, Y. and See, W. A.: Stable overexpression of TGF beta 1 in a transitional carcinoma cell line: impact on fibronectin production. J Urol, 160: 230, 1998
15. Luo, Y., Szilvasi, A., Chen, X., DeWolf, W. C. and O'Donnell, M. A.: A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin Diag Lab Immunol, 3: 761, 1996
16. See, W. A., Yong, X., Crist, S. and Hedican, S.: Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines. J Urol, 151: 1691, 1994
17. Chen, F.-H., Crist, S. A., Zhang, G.-J., Iwamoto, Y. and See, W. A.: Interleukin-6 production by human bladder tumor cell lines is up-regulated by bacillus Calmette-Guerin through nuclear factor κb and AP-1 via an immediate early pathway. J Urol, 168: 786, 2002
18. Kavoussi, L. R., Brown, E. J., Ritchey, J. K. and Ratliff, T. L.: Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest, 85: 62, 1990
19. Fleischmann, J. D., Park, M. C. and Hassan, M. O.: Fibronectin expression on surgical specimens correlated with the response to intravesical Bacillus Calmette-Guerin therapy. J Urol, 149: 268, 1993
20. Danisman, A., Bulut, K., Kukul, E., Ozen, I. and Sevuk, M.: Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. Urol Int, 64: 198, 2000